TABLE 2.

The richness, phylogenetic diversity, and Shannon diversity in non-small cell lung cancer patients and healthy individuals.

Group	Richness	Phylogenetic diversity	Shannon diversity
H	161 ± 39	12.25 ± 2.18	4.44 ± 0.83
T1	125 ± 39	9.84 ± 2.65	3.97 ± 0.96
T2	136 ± 56	10.87 ± 3.34	3.63 ± 1.82
T3	127 ± 55	9.81 ± 3.48	4.20 ± 0.85
T4	142 ± 47	11.01 ± 3.45	4.45 ± 0.83
T5	153 ± 41	11.52 ± 2.49	4.72 ± 0.53
T6	148 ± 61	11.61 ± 3.63	4.30 ± 1.34
T7	127 ± 49	10.14 ± 3.32	4.10 ± 0.82
T8	132 ± 46	10.16 ± 2.73	4.15 ± 0.69
T9	123 ± 41	10.03 ± 2.42	3.78 ± 0.78
T10	127 ± 64	10.12 ± 4.19	3.67 ± 1.33

H represents the healthy individuals; Tn (n = 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10) represents the non-small cell lung cancer patients in different cycles of osimertinib therapy.